Retatrutide is not yet an approved pharmaceutical product. All dosing data currently comes from clinical trial settings — Phase 1 and Phase 2 trials — which provides a research-derived reference framework for understanding how the compound has been studied. This article reviews that framework.
The landscape of GLP-1-based peptides has evolved rapidly. Where semaglutide established the clinical value of sustained GLP-1 receptor agonism, tirzepatide added GIP receptor co-activation, and retatrutide has extended the approach further to include the glucagon receptor. Each addition changes not just the potency but the character of the metabolic response. This article examines all three side by side.
Retatrutide — referred to in some research contexts as GLP-3, reflecting its triple receptor mechanism — is a synthetic peptide designed to activate three distinct G protein-coupled receptors simultaneously: the…